Skip to content

Drug Developer's Intelligence Report

Oncology DRUG REPORT

2021

Two Reports providing complete landscape on oncology drug development

2010

Oncology Drug Developers Worldwide

Single Source Solution to Identify & Connect with Largest Number of Active Oncology Drug Development Companies.

oncology Drug intelligence - 2021 (Sixth Updated Edition)

Report Covers all Aspects of Cancer Drug Development Intelligence

COMPANIES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING

Oncology drug intelligence 2021
largest coverage

providing intelligence at fingertips

1
Countries

Worldwide 33 Countries Covered. Largest Coverage Guaranteed

1
Drug developers

1009 Active Clinical & 1001 Preclinical Stage Oncology Companies Profiled 

1 +
Molecules in Development

Individual Drug Mechanism of Action & Drug Target

1 +
Cancer Targets

Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies

Perfect B2B Solution

Unique first in class Intelligence Report

Provides Complete Landscape on Latest Immuno-Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status in the Domain.
Also, Startups having proper funding, technologies and pipeline are only included.
No Acquired, Merged or Dormant Stage I/O Drug Developer is included.

intelligence supercharged

1835 pages full of insights

01

Oncology Reports

Data Intelligence Derived from

  • 2200+ Active Cancer Drug Developers.
  • 800+ Oncology Research supporting CROs
  • 600+ Venture Investors
  • 450+ Oncology Focused Events

 

RELEASED REPORTS

Ideas We Stand for:

Global Top 400 Immuno Oncology Startups 2020
Provides Complete Landscape on Latest Immuno-Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status among Startups.

Price – $ 3200 USD (Save $1000 USD use “FIRST1000” at checkout).

Released – October 2019

Check Inside Report

Also Check – Immuno Oncology Drug Developer CRM

Global Top 500 Oncology Startups 2017
Top 500 Oncology Startups Drug Developers established between 2010-2016.
First Innovative Report Helping You to Early Identify Startups & Partner with Them.

Price – $ 2800 USD (Save $1000 USD use “FIRST1000” at checkout).

Released – September 2016

Check Inside Report

Also Check – Oncology Startups CRM

Oncology Intelligence 2017 – Comprehensive Intelligence Report for Decision Making
Comprehensive Decision Making Intelligence derived from Active 1047 Oncology Drug Developers.
OI 2017 is a key update over previous report OI 2014, as it may covers 220 more oncology drug developers than the previous report. It also abandoned 103 companies, which were earlier covered in OI 2014, which were either acquired/merged or closed during the period.

Price – $ 3400 USD (Save $1000 USD use “FIRST1000” at checkout).

Released – January 2017

Check Inside Report

Also Check – Oncology Startups CRM

Oncology Intelligence 2014 – Comprehensive Intelligence Report for Decision Making
Comprehensive Decision Making Intelligence derived from Active 931 Oncology Drug Developers.
OI 2017 is a key update over previous report OI 2013, as it may covers 3398 more oncology drug developers than the previous report. It also abandoned 91 companies, which were earlier covered in OI 2013, which were either acquired/merged or closed during the period.

Price – NOT FOR SALE / AVAILABLE ON REQUEST

Released – January 2014

Check Inside Report

Oncology Intelligence 2013 – Comprehensive Intelligence Report for Decision Making
Oncology Intelligence 2013, was the first report in the series derived from Active 624 Oncology Drug Developers.

Price – NOT FOR SALE / AVAILABLE ON REQUEST

Released – January 2013

Check Inside Report

Oncology Drug Funding 2013
Report for the first time covers ‘ONCOLOGY FOCUSED’ 321 Active Venture Capital Firm Profiles their oncology investment portfolio | Criteria | Geographic focus etc.
Price – Freely Available for Download
Released – March 2013 Check Inside Report Also Check – Venture Investors in Drug Development – CRM

Need of the Report

  • From last few years maximum number of Startups are opting for Immuno-Oncology drug discovery challenge.
  • Higher Collaboration to aid drug development process: Immuno-Oncology drug discovery is evolving and requires timely strong support and inputs across the channel.
  • Well-funded, thus offers immense partnering opportunities, but lacks proper system to track emerging opportunities.
  • Currently available resources cover only limited number of known companies that too developing late stage clinical molecules. But real challenge lies in timely identifying the startup, having potential of future shining star.
  • Virtually no system to track, Startups outside U.S and China, which contributes to 30% of total established startups in I/O domain.

Report is highly precise and designed keeping in mind to keep information intact, informative and self explanatory. Also, every piece of intelligence is cross validated.

Only facts, no guess work.

330+ Pages present complete picture of individual company’s pipeline, deals, partnering, funding etc. and outline individual startup’s core strength and stand with respect to other startups.

Report documents all I/O focused news/deals of every startups since incorporation. Making it perfect tool for Decision Making and a big time saver too.

Compares Oranges with Oranges.

Only Active I/O Drug Developing Startups, with no room to Diagnostic and Device companies; making data clear and impactful.

Most of the intelligence provider covers limited number of known companies, that too many of which have no links to the core title of the report. Also many renowned database too contains acquired/closed companies, thus driving final intelligence too tedious and time consuming exercise.

All our reports provides comprehensive intelligence, with largest active industry coverage and avoids investing money on other similar resources. Thus, saves lots of resources in terms of time and money, in identifying new partnering opportunities.

Each year, we publish very small number of comprehensive reports and are experts in identifying and tracking startups. We maintain our own database and track’s every individual company.

From last 10 years, our team exclusively providing marketing intelligence in field of Oncology and Neurology Drug Development.

Limited Time Offer Save 45% (Year-end Promotion)

Sixth Updated Edition - oncology intelligence 2021 Report

Report Covers all Aspects of Cancer Drug Development Intelligence

COMPANIES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING

OI 2021 Vs OI 2020
(in terms of Oncology Drug Developers Number)

UPDATED DATA for
ACCURATE DECISIONS

OI 2021 is a key update over previous report OI 2020, as it may covers 520 more oncology drug developers than the previous report. It also abandoned 110 companies, which were earlier covered in OI 2020, which were either acquired/merged or closed during the period.

Previous Reports in this Series

Oncology Drug Report 2021
Comprehensive Decision Making Intelligence derived from Active 2010 Oncology Drug Developers.
Oncology Drug Report 2020
Comprehensive Decision Making Intelligence derived from Active 1610 Oncology Drug Developers.
Oncology Intelligence 2017
Comprehensive Decision Making Intelligence derived from Active 1047 Oncology Drug Developers.
Oncology Intelligence 2014
Comprehensive Decision Making Intelligence derived from Active 931 Oncology Drug Developers.
Oncology Intelligence 2013
Comprehensive Decision Making Intelligence derived from Active 624 Oncology Drug Developers.
May 2021
Feburary 2020
January 2017
March 2014
January 2013